Cell Source, Inc. (CLCS)

OTCMKTS · Delayed Price · Currency is USD
0.4000
-0.0610 (-13.23%)
Jul 25, 2025, 1:50 PM EDT
-13.23%
Market Cap19.39M
Revenue (ttm)n/a
Net Income (ttm)-6.57M
Shares Out48.47M
EPS (ttm)-0.16
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume500
Average Volume9,889
Open0.4000
Previous Close0.4610
Day's Range0.4000 - 0.4000
52-Week Range0.0008 - 0.8401
Beta-200.34
RSI55.42
Earnings DateSep 3, 2025

About Cell Source

Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company’s Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disea... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Itamar Shimrat
Employees 1
Stock Exchange OTCMKTS
Ticker Symbol CLCS
Full Company Profile

Financial Performance

Financial Statements

News

Cell Source Presents Potential Breakthrough in the Development of Off-the-Shelf CAR-T Cell Therapy at American Society of Hematology Annual Meeting

Research Presented at the American Society of Hematology Annual Meeting Highlights New Mechanisms to Overcome Immune Rejection NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Cell Source, Inc. (OTCQB:...

7 months ago - Accesswire